Answers are grounded in this paper and cite their sources.
Novel deep learning method improves PAM50 subtype classification in breast cancer, highlighting multi-omics data integration.
Accurate molecular subtyping of cancer is crucial for advancing personalized medicine. Although multiomics data contain valuable predictive information, effectively integrating them is challenging due to differences across modalities, high dimensionality, and complex cross modal biological interactions. We propose HyperCLSA (Hypergraph Contrastive Learning with Self-Attention), a novel deep learning framework for efficient multi-omics integration in breast cancer subtyping. HyperCLSA combines hypergraph-based sample encoding, supervised contrastive learning for latent space alignment, and multi-head self-attention for adaptive fusion of omics modalities. Evaluated on The Cancer Genome Atlas (TCGA) Breast Cancer dataset for PAM50 subtype classification, HyperCLSA achieves a significant performance improvement over state-of-the-art baselines. Our results demonstrate HyperCLSAs effectiveness in extracting complementary information across heterogeneous omics sources, providing a robust framework for molecular characterization of breast cancer.
No takes yet. Share an insight, caveat, or question.
Bhole et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: